Business UpdateMay 4, 2026, 07:01 AM
Glaukos Projects 2026 Sales of $627.5M; Highlights Strong Pipeline
AI Summary
Glaukos Corporation presented an investor update highlighting its strong growth trajectory and robust product pipeline. The company projects a 2026 sales guidance midpoint of $627.5 million, building on 30% topline growth in 2025 and a 20% 10-year revenue CAGR. Key advancements include the FDA approval for re-administration of iDose TR in January 2026 and the commercial launch of Epioxa for keratoconus in March 2026. The company also reported a healthy balance sheet with $281 million in cash and no debt.
Key Highlights
- Projects 2026 sales guidance midpoint of $627.5 million.
- Achieved 30% topline growth in 2025 and a 20% 10-year revenue CAGR.
- iDose TR received FDA approval for re-administration in January 2026.
- Epioxa, an epithelium-on treatment for keratoconus, became commercially available in March 2026.
- iDose TRIO completed patient enrollment in its Phase 3b study.
- iDose TREX is advancing its Phase 2b/3 clinical program.
- Reports $281 million in cash and equivalents with no debt as of March 31, 2026.